P505 - Glycemic Improvement with Use of the Omnipod® 5 Automated Insulin Delivery (AID) System in Adults with Type 2 Diabetes: Results of the SECURE-T2D Pivotal Trial

There is limited data on the use of AID in type 2 diabetes. This poster discusses a multicenter pivotal clinical trial to evaluate use of the Omnipod 5 AID System in a large, diverse group of adults with type 2 diabetes (n=305) treated with insulin therapy in the US. Following a 2-week standard therapy phase, participants completed 13 weeks of AID use. HbA1c was reduced by 0.8% (from 8.2% at baseline to 7.4% after AID). Improvements in HbA1c were observed across a variety of subgroups including age, sex, race/ethnicity, carbohydrate counting method, and those using other anti-hyperglycemic medications. These findings demonstrate the substantial benefit of Omnipod 5 use in a large, diverse group of adults with T2D and support the use of AID technology in this population.